24.60 -0.18 (-0.73%)
After hours: 6:20PM EDT
|Bid||24.40 x 1300|
|Ask||24.94 x 2200|
|Day's Range||23.10 - 24.94|
|52 Week Range||7.73 - 26.77|
|Beta (3Y Monthly)||3.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2018 - Feb 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.13|
U.S. stock indices were again quiet on Wednesday, as we begin to chip away at the tip of the earnings iceberg. We're mostly delving through the banks right now, but will have tech and other industries beginning soon. Let's look at a few top stock trades. Top Stock Trades for Tomorrow 1: Tesla Click to EnlargeTesla (NASDAQ:TSLA) stock has been moving favorably, working on its seventh straight week of gains. InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt's getting into a very key area though, the $250 to $260 zone. This was prior range support for years, buoying Tesla stock on each test. Back in May, the stock plunged below this mark, rebounded the next week and failed to reclaim it. * 4 Retail Stocks to Buy in Time for the Back-to-School Rush This is all shown via the purple arrow on the chart and shows when an area shifts from support to resistance. Now back in this area, it's vital for TSLA stock to reclaim this range level in order to keep the rally alive. Those who bought Tesla sub-$200 as a trade may consider booking some profits here. Should shares push through, look for a rally up to the 200-week moving average, currently at $273. On a pullback, see that the 10-week holds as support. I wouldn't want to see Tesla below $240. Top Stock Trades for Tomorrow 2: Abbott Labs Click to EnlargeAbbott Labs (NYSE:ABT) hit new highs after the company reported earnings. However, the stock is not moving as robustly as one might have expected. I want to see ABT stock hold $85 on the downside and see if it can push up to channel resistance on the upside. Top Stock Trades for Tomorrow 3: Gold Click to EnlargeThe move has been years in the making, but the SPDR Gold ETF (NYSEARCA:GLD) is starting to make some waves. The iShares Silver Trust ETF (NYSEARCA:SLV) has been trading well too, but isn't putting together the kind of chart GLD is. Above is a long-term weekly chart. With GLD over the $128 to $130 area, it's in breakout mode. While shares are putting in a nice bull flag setup after a huge burst higher in June, we absolutely need to see prior resistance hold as support. A rate cut should help fuel a rally for gold, although the market is surely starting to price in such an event. Over $135.55 sends GLD even higher. A pullback to $130 or the 10-day moving average that holds as support may be a buy-the-dip opportunity. Top Stock Trades for Tomorrow 4: Invitae Click to EnlargeShares of Invitae (NASDAQ:NVTA) took off Wednesday, rallying up toward $24 at one point in the day. Citron Research said it had a position in the name and is using a $100 price target. We've been telling InvestorPlace readers for months that we love this name. Today's action came with perfect timing. On Twitter on Tuesday, we pointed out that NVTA stock broke below the 20-day moving average, but reclaimed this mark by the close. That was very constructive action, while Wednesday's action has been downright impressive. The action is similar to what we saw last month, where shares broke below the 20-day, reclaimed it in the same session, then went on a monster run over the next few days. I'm not sure that history repeats, but investors are hopeful that it will. Let's see if NVTA can push through $24 to $24.50. If it can, $26+ could be in the cards. Top Stock Trades for Tomorrow 5: Teva Pharmaceutical Click to EnlargeShares of Teva Pharmaceutical (NYSE:TEVA) are taking it on the chin. The stock is down 11% in just three days and more than 20% from its highs earlier this month. * 8 Penny Stocks That Have Fallen From Grace The stock hit new 52-week lows on the move and is threatening to fall below $8 support. Longs with a strong stomach can play against Wednesday's lows, but Teva has not been a great one to own. A break below $8 could accelerate the selling pressure. A rally could bring Teva back up to its 20-day moving average. Above that and $10 is possible. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long NVTA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 5 Top Stock Trades for Thursday: TSLA, GLD, ABT appeared first on InvestorPlace.
Biotech adds 4% to $23.44 after Left, who's better known for his short positions, argues it can go to $100 a share.
A trifecta of perfection: We had record highs in the S&P 500, Dow Jones and Nasdaq today. Shareholders in the PowerShares QQQ ETF (NASDAQ:QQQ) have little to complain about as tech stock continues to mash out higher highs over the past few sessions.Source: Shutterstock That's as FAANG stocks mostly lag and while rate cuts are likely.That said, it's not expected to be an amazing quarter when it comes to earnings. Companies are warning about their upcoming results, while analysts' estimates are looking at year-over-year declines for many names.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBlame it on tough comps from tax cuts, tariff wars or what have you. It's not a perfect operating environment and with stocks near all-time highs, investors are either willing to overlooking a few quarters of underperformance and pay a higher valuation for earnings or they area simply too optimistic. We'll know soon enough when we start seeing these companies report. Facebook SettlementFacebook (NASDAQ:FB) shares spiked into the close on Friday, ending the session higher by 1.8%. Reports surfaced moments before the close that the company had come to terms on a $5 billion settlement with the FTC. The deal is expected to have some other privacy restrictions as well. * 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond While $5 billion is a lot of cabbage, it's roughly the same amount that FB set aside to pay for such an event. Clearing this obstacle removes an unknown event for investors, who like clarity and having uncertainty removed. Movers in the Nasdaq TodayIllumina (NASDAQ:ILMN) shares sank more than 15% on the day after the company warned about its upcoming results. This caught investors way off guard, considering the company just beat and raised estimates a few months ago. It's not a good look for the genomics company, as it now hovers in no man's land. (Here's the trade setup for ILMN stock now).One could argue that it also weighed on Invitae (NASDAQ:NVTA), although the company's $50 million acquisition could be what's shaking up the stock price. Down 1.75% on the day, it's at least worth pointing out.Square (NYSE:SQ) stock jumped almost 4% on Friday, giving it a 10% gain over the past few days. The stock has seen some positive analyst commentary over the past few days, with the latest coming from Citigroup on Friday. While the stock is running into some resistance, many have it on breakout watch.JB Hunt (NASDAQ:JBHT) caught a big bid on Friday, rising over 6% on the day. However, currently trading hands for around $93 apiece, shares are well off the 52-week highs near $130. Be careful with this one, which reports earnings Monday.The $45 billion technology consulting company Infosys (NYSE:INFY) reported earnings on Friday. Shares hit new 52-week highs on the day, despite missing revenue estimates and reporting in-line earnings results. Better-than-expected guidance and an increase in its capital return plan likely helped, though.Memory and memory equipment stocks were also in focus in the Nasdaq today, as Lam Research (NASDAQ:LRCX), Western Digital (NASDAQ:WDC) and Micron (NASDAQ:MU) all put together a strong session. Micron is flirting with prior resistance, but a move over $44 to $45 could trigger a breakout. All About AmazonShares of Oracle (NASDAQ:ORCL) slipped 30 basis points on Friday after the company lost its court case against the Pentagon. The $10 billion cloud contract will now go to either Amazon (NASDAQ:AMZN) or Microsoft (NASDAQ:MSFT). But that's far from the only reason Amazon stock is in the news day.First, the company's much-discussed Prime Day is set to start next week. Prime Day will kick off on July 15th and run through the 16th. The made-up shopping event isn't unlike Alibaba's (NYSE:BABA) Single's Day, while Amazon now attracts others competitors into mix as well. Companies like Best Buy (NYSE:BBY), Target (NYSE:TGT) and Walmart (NYSE:WMT) will be running specials too, trying to keep customers away from the e-commerce juggernaut.As the smart-speaker battle heats up, Amazon is reportedly looking to better its game. The company wants to roll out a high-end Echo device, which could arrive next year. Further, Amazon is also working on an Alexa-powered robot. Codenamed Vesta, the devices apparently will not be ready for mass production this year. * 7 Stocks to Buy for Monster Growth in the Second Half of 2019 Last but certainly not least, Amazon's game-streaming Twitch platform logged more than 2.7 billion hours worth of streaming in the second quarter. For the industry, that accounted for more than 70% of the total. The next closest was Alphabet's (NASDAQ:GOOG, NASDAQ:GOOGL) YouTube Live at 735 million hours and 19.5% market share. It was Twitch's second-biggest quarter ever.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AMZN and GOOGL. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Buy for Less Than Book * 7 Marijuana Stocks With Critical Levels to Watch * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond The post Nasdaq Today: Amazon Prime Day; Facebook Settles With FTC appeared first on InvestorPlace.
After purchasing Singular Bio in June, InVitae Corp (NYSE: NVTA ) now plans to acquire Jungla, which would add to its hereditary cancer testing capabilities, according to Benchmark. The Analyst Bruce Jackson ...
SAN FRANCISCO, July 11, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Jungla Inc., a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of genetic and genomic tests. The combination is expected to further enhance Invitae's genetic variant interpretation and ability to deliver high-quality, more affordable genetic testing for use in mainstream medical care.
2019 has been a rocky year for the healthcare industry. The general healthcare market sell-off combined with criticism over high costs poses a cause for concern. Despite the lackluster performance of many healthcare stocks so far in 2019, there are a few standouts with long-term growth potential. Using data from TipRanks, we’ve narrowed down three stocks in the healthcare space that analysts believe are well positioned for future growth. Boston Scientific Corporation (BSX)Unlike other stocks in the healthcare industry, Boston Scientific shares saw significant growth over the last year. The medical equipment manufacturer’s stock increased 22.5% while the industry as a whole saw only a 4% increase. In the quarter ending March 31, the company reported calendar year increases in revenue and net profit. Revenue was up from $2.38 billion to $2.49 billion while net profit increased from $298 million to $424 million.Boston Scientific’s long-term growth plan, which includes projections of double digit adjusted EPS growth through 2020, gives analysts reason to believe the company will continue to outperform. Raj Denhoy, a top analyst from Jeffries, raised his price target from $44 to $48 stating that the company’s projections from their investor meeting were “another positive look at a story that has been in sharp ascendancy for the last five years.” He added that the projections are even somewhat conservative given the company’s stability and the addition of new products in the next few quarters. Another five-star analyst, Matt Miksi of Credit Suisse, explained that he is unsurprised by Boston’s success when discussing the company’s sale of various products from their portfolio to Varian for $90 million. He maintained the stock’s Outperform rating and $45.00 price target, indicating a 5.56% upside. The Street’s outlook on the stock is bullish, with 10 analysts from TipRanks giving a buy rating vs just 1 hold over the last three months. The stock boasts a ‘Strong Buy’ analyst consensus and an average price target of $45.63, suggesting a 7.04% upside. View BSX Price Target & Analyst Rating Details Invitae Corporation (NVTA)Invitae is an innovative biotech company in the genetic testing segment of the market whose goal is to make genetic screenings more affordable and accessible. Five-star financial blogger, Todd Campbell, notes that the company cut the cost of goods sold by upwards of 20% over the last year as well as reported year-over-year sales of $148 million, a 117% increase. Management is projecting sales of $220 million in 2019 and a test volume of 500,000. Additionally, the company announced on June 17 that they are set to acquire Singular Bio. “The acquisition of Singular Bio gives Invitae a critical technology that can turn the NIPS business into a 50% gross margin performer once fully integrated into the firm’s process, and if you broke out Invitae's cancer business, it turned a profit as a standalone business as of Q1 of this year,” stated Sean George, the company’s CEO. Five-star rated Cowen & Co. analyst, Doug Schenkel, is confident in the stocks ability to grow, reiterating his Outperform rating and $30.00 price target. He believes Singular Bio’s “flexible, quick, and less expensive technology will give Invitae a competitive advantage over other companies with sequencing-based and microarray-based approaches for some applications including NIPS/NIPT.”The consensus among analysts is that the stock is a ‘Strong Buy’, with an average price target of $30.00, suggesting a 23.61% upside. View NVTA Price Target & Analyst Rating Details Teladoc Health, Inc. (TDOC)The last stock on our list doesn’t appear to be slowing down any time soon. Teladoc meets the growing demand for healthcare access in a cost-effective way by providing virtual medical care through telephone and videoconferencing technology. Share prices surged by 35.73% year-to-date. Management is confident that this growth will continue throughout the rest of the year. Based on Teladoc’s recent acquisitions as well as their competitive advantage within this segment of the healthcare sector, management is anticipating 37% revenue growth. In the most recent quarter, the company reported 29% organic growth with 1,063,000 total visits. Richard Close, an analyst at Canaccord Genuity, believes that the telemedicine company’s “penetration into its existing client base will allow it to generate robust organic growth.” He maintains his buy rating on the stock and price target of $95.00 (41.20% upside). Five-star Piper Jaffray analyst, Sean Wieland, remains bullish on the stock. He explained that he views the completion of their CFO search and an impending United deal as “two important catalysts and remains a buyer of the stock in front of them.” He reiterated his Overweight rating and price target of $86.00, suggesting a 27.82% upside.While the on-demand remote medical care provider isn’t profitable yet, analysts believe in Teladoc’s growth potential. The stock has a ‘Strong Buy’ analyst consensus, with 12 out of 13 analysts on TipRanks giving a buy rating. The average price target of $79.83 shows that analysts believe the stock price could increase by 18.65%. View TDOC Price Target & Analyst Rating DetailsFind your own best investment with TipRanks’ Analysts’ Top Stocks page.
LOS ANGELES, June 27, 2019 -- In an interview with Capital Market Laboratories (CMLviz), chief executive officer of Invitae (NYSE:NVTA) Sean George had a clear message: Invitae.
A day after the Fed's statement on Wednesday, the stock market ripped higher Thursday. On Friday, it cautiously hovered around flat as investors contemplate the Fed, the trade war and potential geopolitical issues with Iran. That said, there are some solid moves in individual names, leading the way for our top stock trades. Top Stock Trades for Tomorrow 1: Apple Click to EnlargeI really like the way Apple (NASDAQ:AAPL) is coiling just below $200. The FANG + Apple group came into Friday's session 13% or more below their all-time highs, with the exception of Amazon (NASDAQ:AMZN), which was about 6% below its highs.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Boring Stocks to Buy This Summer It will be hard for the Nasdaq to hit new highs with this lagging action under way. If the trade-war rhetoric starts to improve though, AAPL could be a big winner.Over $200 puts $210+ on the table. If $200 is resistance though, look for trend and moving average support between $192.50 and $194. Otherwise, AAPL may need more time to setup. Top Stock Trades for Tomorrow 2: Exxon Mobil Click to EnlargeAbove is a long-term weekly chart of Exxon Mobil (NYSE:XOM). While not displayed, the stock barely reclaimed and closed above both its 50-day and 200-day moving average on Thursday. On Friday, it added to those gains, as it's now over the 50-week moving average as well (that's actually shown above).So now what?I want to see if XOM can put together a rally up toward $80, currently downtrend resistance (blue line). Above that mark calls for a test of range resistance near $83. Should shares falter from current levels, a decline to its 200-week moving average near $75 is in play. Below that and uptrend support around $73 is on the table, with range support at $70 just below that.Keep it simple and visual. Top Stock Trades for Tomorrow 3: Invitae Click to EnlargeInvitae (NASDAQ:NVTA) really burst onto the scene this year, running from about $10 in January to $26.77 in April. Wow, what a run! But the whole long setup fell apart when a head-and-shoulder formation sent shares reeling once neckline support near $22.50 gave way.Since then, $17 support held up fine as shares have been making their way higher once again. Friday's action looked disappointing, but long-term bulls have to be happy with it holding its 20-day and 50-day moving averages.NVTA is a speculative holding, but looks set for big long-term gains in my view.I would love to see it push through this $22 to $22.50 area, which marks prior neckline support as well as downtrend resistance (blue line). If it does, look for a gap fill up toward $24. If it can't push through $22.50, see if its moving averages can buoy the name again. Top Stock Trades for Tomorrow 4: The Trade Desk Click to EnlargeAnother high-octane growth name has been The Trade Desk (NASDAQ:TTD).Earlier this month, we called TTD a better sell than buy up near $260 channel resistance. While it wasn't overbought, going from $200 to $260 in just five trading sessions was too far, too fast.Momentum is starting to roll over (blue circle) and TTD is coming under pressure. I don't know if the 20-day saves it or if it will fall to the 50-day. Will it return to $200? I really don't know -- no one does.However, bulls who wisely took profits can start to rebuild a position near any of these key levels. It just depends on how comfortable they feel with the potential risk. $231 marked the recent low this month, so perhaps the 20-day isn't a bad spot to nibble. I would love another shot at TTD closer to $200 though. Top Stock Trades for Tomorrow 5: Nio Click to EnlargeThis is another one we recently warned investors about. Nio (NASDAQ:NIO) stock rallied up to prior downtrend support and the 20-day moving average.On Friday, these marks ruthlessly swatted Nio lower, as shares collapsed more than 8%. Now the $2.50 level is back on the table. Below and Nio stock will look quite ugly. Simply put, this is not one I want to be long. * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 If $2.50 holds, we need to see a move over the 20-day and downtrend resistance before it's even close to being a buy.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AAPl and AMZN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Best Dow Jones Stocks to Buy for the Rest of 2019 * 5 Boring Stocks to Buy This Summer * 7 S&P 500 Stocks to Buy With Little Debt and Lots of Profits Compare Brokers The post 5 Top Stock Trades for Monday: AAPL, XOM, NVTA appeared first on InvestorPlace.
The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health
SAN FRANCISCO, June 20, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that it granted time-based and development milestone-based restricted stock units ("RSUs") to new employees who joined Invitae in connection with its acquisition of Singular Bio, Inc. The RSUs were granted under Invitae's 2015 Stock Incentive Plan, which was amended and restated to create an additional pool of shares of Invitae common stock to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). The RSUs were approved by the Board of Directors of Invitae and were made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08.
Invitae (NYSE: NVTA ) will acquire Singular Bio for $55 million in a mostly stock deal. Invitae is medical genetics company and Singular Bio is a privately held company developing single molecule detection ...
SAN FRANCISCO, June 17, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio, Inc., a privately held company developing single molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive prenatal screening (NIPS). "Since we began, Invitae has invested deeply to harness the power of the most advanced genetic testing technologies in order to deliver expert-level genetic information at scale, and bringing this company into Invitae is the next step in that process," said Sean George, PhD, co-founder and chief executive officer of Invitae.
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]
X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Invitae Corporation (NVTA), a leader in medical genetics, today announced a partnership to provide genetic testing at no cost to patients through its collaborative PATH4WARD program. This initiative provides greater access to faster and earlier diagnosis for individuals who may carry a genetic mutation known to be associated with WHIM syndrome and Severe Congenital Neutropenia (SCN) – a group of rare inherited primary immunodeficiencies (PIs).
SAN FRANCISCO, June 12, 2019 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced the launch of ID YOUR IRD, an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD), a group of rare, progressive eye disorders that may result in vision loss or blindness and are caused by inherited genetic changes.
As genetic testing explodes, this telehealth company's network of doctors — both in-house and with partnering hospitals and health systems — is identifying what test results mean and mapping out treatment plans.
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.